Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects.
Mirza MR, Lindahl G, Mahner S, Redondo A, Fabbro M, Rimel BJ, Herrstedt J, Oza AM, Canzler U, Berek JS, González-Martín A, Follana P, Lord R, Azodi M, Estenson K, Wang Z, Li Y, Gupta D, Matulonis U, Feng B. Mirza MR, et al. Among authors: azodi m. Cancer Res Commun. 2022 Nov 15;2(11):1436-1444. doi: 10.1158/2767-9764.CRC-22-0240. eCollection 2022 Nov. Cancer Res Commun. 2022. PMID: 36970052 Free PMC article.
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Moore KN, et al. Among authors: azodi m. Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Lancet Oncol. 2019. PMID: 30948273 Clinical Trial.
Glyceraldehyde-3-phosphate dehydrogenase binds to the AU-Rich 3' untranslated region of colony-stimulating factor-1 (CSF-1) messenger RNA in human ovarian cancer cells: possible role in CSF-1 posttranscriptional regulation and tumor phenotype.
Bonafé N, Gilmore-Hebert M, Folk NL, Azodi M, Zhou Y, Chambers SK. Bonafé N, et al. Among authors: azodi m. Cancer Res. 2005 May 1;65(9):3762-71. doi: 10.1158/0008-5472.CAN-04-3954. Cancer Res. 2005. PMID: 15867372
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Bellone S, et al. Among authors: azodi m. Cancer. 2009 Feb 15;115(4):800-11. doi: 10.1002/cncr.24048. Cancer. 2009. PMID: 19117353 Free article.
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin-Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD. Casagrande F, et al. Among authors: azodi m. Cancer. 2011 Dec 15;117(24):5519-28. doi: 10.1002/cncr.26215. Epub 2011 Jun 20. Cancer. 2011. PMID: 21692061 Free PMC article.
Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Roque DM, et al. Among authors: azodi m. Cancer. 2013 Jul 15;119(14):2582-92. doi: 10.1002/cncr.28017. Epub 2013 Apr 12. Cancer. 2013. PMID: 23585021 Free PMC article.
Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
Craveiro V, Yang-Hartwich Y, Holmberg JC, Joo WD, Sumi NJ, Pizzonia J, Griffin B, Gill SK, Silasi DA, Azodi M, Rutherford T, Alvero AB, Mor G. Craveiro V, et al. Among authors: azodi m. Cancer Med. 2013 Dec;2(6):751-62. doi: 10.1002/cam4.115. Epub 2013 Aug 27. Cancer Med. 2013. PMID: 24403249 Free PMC article.
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. English DP, et al. Among authors: azodi m. Cancer. 2015 Feb 1;121(3):403-12. doi: 10.1002/cncr.29062. Epub 2014 Sep 23. Cancer. 2015. PMID: 25251053 Free PMC article.
Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.
Altwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES. Altwerger G, et al. Among authors: azodi m. J Cancer Res Clin Oncol. 2018 Dec;144(12):2449-2456. doi: 10.1007/s00432-018-2753-y. Epub 2018 Sep 25. J Cancer Res Clin Oncol. 2018. PMID: 30255380
A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi DA, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario JR, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. Bellone S, et al. Among authors: azodi m. Cancer. 2022 Mar 15;128(6):1206-1218. doi: 10.1002/cncr.34025. Epub 2021 Dec 7. Cancer. 2022. PMID: 34875107 Free PMC article. Clinical Trial.
185 results